HIF-2α Inhibitor Scaffold for Selective Hypoxia Pathway Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with Hypoxia-Inducible Factor 2α (HIF-2α) activity, such as cancer, inflammatory bowel disease (IBD), nonalcoholic steatohepatitis (NASH), pulmonary arterial hypertension (PAH), and iron load disorders, lack specific inhibitors that can effectively target HIF-2α without affecting HIF-1α, leading to potential toxicity and limited therapeutic efficacy.
Innovation Solution
Development of tetrahydro-1H-cyclopenta[cd]indene compounds that selectively inhibit HIF-2α, providing therapeutic benefits for diseases like renal cancer, glioblastoma, NASH, PAH, and iron overload by targeting HIF-2α pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum HIF inhibitors are used to treat hypoxia-related diseases, then multiple HIF pathways are inhibited, but non-specific toxicity increases and therapeutic selectivity decreases
Solution Approach 1:
The patent segments the HIF inhibition function into two distinct parts: HIF-1α inhibition and HIF-2α inhibition. By designing compounds that selectively target HIF-2α while sparing HIF-1α, the invention achieves disease-specific therapeutic effects without the non-specific toxicity associated with broad-spectrum HIF inhibitors. This selectivity is accomplished through specific molecular structural features that preferentially bind to HIF-2α.
Solution Approach 2:
The patent applies local quality by introducing specific substituent patterns at particular positions on the core molecular structure. These localized chemical modifications (such as specific R-group substitutions on the aromatic rings) create compounds with enhanced HIF-2α selectivity, allowing the molecule to interact differently with HIF-1α versus HIF-2α based on the local chemical environment provided by these substituents.
2Reliability
If HIF-1α is inhibited to treat cancer, then angiogenesis and cell proliferation are suppressed, but essential physiological functions are disrupted
Solution Approach 1:
The patent extracts the HIF-2α inhibition function from the broader HIF inhibition category, creating a therapeutic agent that specifically targets HIF-2α while leaving HIF-1α intact. This extraction allows the drug to address HIF-2α-driven pathologies (such as certain cancers, polycythemia, and pulmonary hypertension) without interfering with HIF-1α-mediated essential physiological processes like wound healing and immune response.
Solution Approach 2:
Instead of inhibiting HIF-1α as has been the traditional approach in cancer therapy, the patent inverts the strategy by selectively inhibiting HIF-2α. This inversion recognizes that HIF-2α, rather than HIF-1α, is the primary driver of many hypoxia-related diseases, and that preserving HIF-1α activity maintains essential physiological functions while still achieving therapeutic benefit.
3Reliability
If pan-HIF inhibition is employed, then downstream hypoxia effects are broadly blocked, but off-target effects increase and therapeutic window narrows
Solution Approach 1:
The patent segments the hypoxia response pathway inhibition into HIF-1α-specific and HIF-2α-specific components. By designing compounds that preferentially inhibit HIF-2α, the invention blocks downstream hypoxia effects that are HIF-2α-dependent (such as erythropoietin production, vascular endothelial growth factor expression, and certain oncogenic pathways) while avoiding off-target effects on HIF-1α-dependent processes.
Solution Approach 2:
The patent utilizes parameter changes in the molecular structure of the compounds to achieve HIF-2α selectivity. By modifying parameters such as substituent types, positions, and stereochemistry on the core molecular scaffold, the invention tunes the compound's affinity and selectivity for HIF-2α versus HIF-1α, thereby achieving effective hypoxia pathway inhibition with minimal off-target effects.
Data Source
AI summary
The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.